No more than $75 million!

Recently, Huadong Medicine announced that its wholly-owned subsidiary Sino-US Huadong has reached a major strategic cooperation with AKSO Biopharmaceutical, a global biopharmaceutical company in the United States.
Huadong Medicine will obtain the latter's global innovative drugs under development for a total amount of not more than 75 million US dollars.
Exclusive clinical development and commercialization rights for AB002 (for solid tumor therapy) in Asia Pacific (excluding Japan)
.
Huadong Medicine will jointly guide the clinical trial application work with AKSO through the Joint Research Committee
.
AB002 is a preclinical dual-target fusion protein targeting PD-L1/L2 and IL15, comprising a DEEP technology platform engineered mutated soluble PD-1 (for immune checkpoint inhibition) and an IL- 15 Agonists (for activation of NK cells)
.
According to reports, AB002 can capture PD-L1 and PD-L2 with ultra-high binding affinity, while targeting delivery of IL-15 agonists to tumor cells.
Its ability to precisely target tumor cells avoids the activation of systemic NK cells, while Extends the half-life of IL-15 agonists
.
AB002 inhibits immune checkpoints and activates natural killer cells to treat solid tumors
.
Huadong Medicine is an enterprise with global innovative drug layout in the three core therapeutic areas of anti-tumor, endocrine and autoimmunity.
The oncology field is the company's key strategic area.
The company has many years of experience in the development and industrialization of oncology drugs.
The anti-tumor product has been listed
.
In recent years, Huadong Medicine has continued to focus on in-depth and differentiated layout in the field of oncology, with clinical needs and patients as the first, and has successively cooperated with a series of domestic and foreign innovative R&D companies such as ImmunoGen, Provention Bio, Ashvattha, and Nuo Ling Bio
.
Regarding the significance of this strategic cooperation, the company believes that it will further expand the innovative drug research and development pipeline, give full play to the advantages of Huadong Medicine in clinical development, registration and commercialization, and help the company to deepen the layout of the global innovative research and development track
.
Under the guidance of the comprehensive innovation and transformation strategy, Huadong Medicine's innovative drug research and development has entered a rapid development channel, and more and more new drug research and development pipelines are gradually emerging
.
Since the beginning of this year, the good news of Huadong Medicine in the field of oncology has continued
.
In addition to this cooperation, on January 20, Huadong Medicine also issued an announcement that the application for the Phase I clinical trial of DR30303 for injection, a new class 1 biological product declared by the holding subsidiary Doer Biotech, was approved, and the drug indication is Claudin18.
2 positive advanced solid tumors
.
The announcement shows that there is currently no anti-Claudin18.
2 drug on the market in the world
.
Doyle Biotech has obtained the approval notice for the clinical trial of DR30303 for injection, which will enrich the company's product reserves in the field of tumor therapy
.
From the perspective of the general background, the field of tumor immunity is also a large potential market.
There are still large unmet clinical treatment needs of huge tumor patients at home and abroad, which is also the reason why many pharmaceutical companies are attracted to increase their layout
.
In addition to Huadong Medicine, for example, Junshi Bio and Coherus BioSciences recently announced that the two parties will expand the cooperation in the field of tumor immunity in 2021.
Coherus has started the use of JS006 (the anti-TIGIT monoclonal antibody independently developed by Junshi Bio) in the United States and Canada's Licensing Option Program
.
It is reported that Junshi Biosciences has built a rich and complementary product pipeline in the field of tumor immunity.
Through the deepened cooperation with Coherus, the company plans to promote the development of the combination therapy of JS006 and toripalimab in different tumor types as soon as possible
.